TITLE

Multiple Myeloma: Diagnosis and Treatment

AUTHOR(S)
Rajkumar, S. Vincent; Kyle, Robert A.
PUB. DATE
October 2005
SOURCE
Mayo Clinic Proceedings;Oct2005, Vol. 80 Issue 10, p1371
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Major advances have occurred in our understanding of the biology of multiple myeloma (MM) and in its treatment in the past decade. New diagnostic criteria have been developed, and an International Staging System has replaced the Durle-Salmon Staging System. It is now possible to classify MM as standard risk or high risk on the basis of specific independent prognostic factors. The role of single and double autologous stem cell transplantation has been clarified by randomized trials. Most importantly, thalidomide, bortezomib, and lenalidomide have emerged as new active agents and are being incorporated rapidly into the treatment of both newly diagnosed and relapsed MM. The current approach to the diagnosis, prognosis, and management of MM is reviewed.
ACCESSION #
18541563

 

Related Articles

  • Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation. McCormack, Paul // Drugs & Aging;May2015, Vol. 32 Issue 5, p409 

    Lenalidomide (Revlimid) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible...

  • Value of novel agents and intensive therapy for patients with multiple myeloma. Alexanian, R; Wang, M; Delasalle, K; Wang, S; Qazilbash, M; Handy, B; Weber, D // Bone Marrow Transplantation;Mar2014, Vol. 49 Issue 3, p422 

    We conducted a retrospective evaluation of response and survival for 293 patients with multiple myeloma treated since June 2000 with primary thalidomide- or bortezomib-based combinations, of whom 207 patients received intensive therapy supported by autologous blood stem cells within the first...

  • Traitement du myélome multiple. Coiteux, V.; Tricot, S.; Wemeau, M.; Facon, T. // Oncologie;mai2006, Vol. 8 Issue 4, p357 

    The past twenty years have brought continuous progress in the management of care for patients suffering from multiple myeloma (MM). Intensive treatment by autologous peripheral blood stem cell transplantation is now a reference treatment for patients under the age of 65. Since 1999, three new...

  • A man with a fracture from minor trauma. Siu Ming Yang; Chor Man Lo // World Journal of Emergency Medicine;2014, Vol. 5 Issue 4, p306 

    BACKGROUND: We commonly encounter fractures secondary to trauma on and off in our daily practice. While it is not uncommon to see fractures due to underlying pathology, we need to be on the alert when patients present atypically because the treatment for pathological fractures is far different...

  • Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Krejci, M.; Buchler, T.; Hajek, R.; Svobodnik, A.; Krivanova, A.; Pour, L.; Adam, Z.; Mayer, J.; Vorlicek, J. // Bone Marrow Transplantation;Jan2005, Vol. 35 Issue 2, p159 

    Summary:Autologous stem cell transplantation (ASCT) has an established role in the treatment of symptomatic multiple myeloma (MM). Our aim was to analyse the impact of selected prognostic parameters on the survival of patients with MM after ASCT. The new International Staging System (ISS) was...

  • Therapeutic advancements in multiple myeloma. Gozzetti, Alessandro; Candi, Veronica; Papini, Giulia; Bocchia, Monica // Frontiers in Oncology;Sep2014, Vol. 4, p1 

    Multiplemyeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission...

  • Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. Ahn, Seo-Yeon; Jung, Sung-Hoon; Joo, Young; Lee, Won; Lee, Sang; Choi, Chul; Kim, Seok; Kim, Kihyun; Lee, Je-Jung // Annals of Hematology;Sep2014, Vol. 93 Issue 9, p1571 

    This phase II study prospectively evaluated the efficacy and tolerability of an early change in induction therapy before autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients who failed to achieve more than a partial response (PR) after two cycles of a cyclophosphamide,...

  • Decreased body mass index is associated with poor prognosis in patients with multiple myeloma. Jung, Sung-Hoon; Yang, Deok-Hwan; Ahn, Jae-Sook; Lee, Seung-Shin; Ahn, Seo-Yeon; Kim, Yeo-Kyeoung; Kim, Hyeoung-Joon; Lee, Je-Jung // Annals of Hematology;May2014, Vol. 93 Issue 5, p835 

    Obesity increases morbidity in and mortality of patients with various types of cancer. However, the proportion of obese individuals in Asia is smaller than that in Western populations and only a few studies have explored the effect of obesity at the time of diagnosis on the survival of Asian...

  • European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. LUDWIG, HEINZ; AVET-LOISEAU, HERV; BLAD, JOAN; BOCCADORO, MARIO; CAVENAGH, JAMIE; CAVO, MICHELE; DAVIES, FAITH; DE LA RUBIA, JAVIER; DELIMPASI, SOSANA; DIMOPOULOS, MELETIOS; DRACH, JOHANNES; EINSELE, HERMANN; FACON, THIERRY; GOLDSCHMIDT, HARTMUT; HESS, URS; MELLQVIST, ULF-HENRIK; MOREAU, PHILIPPE; SAN-MIGUEL, JESéS; SONDERGELD, PIA; SONNEVELD, PIETER // Oncologist;May2012, Vol. 17 Issue 5, following p592 

    The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics